Progressive or relapsed Hodgkin lymphoma has demonstrated responsiveness to salvage radiotherapy in pediatric patients.
Breast cancer surgeons play a big role in deciding whether women with early-stage breast cancer undergo a controversial operation to have both breasts removed, even when cancer is found in only one.
The National Comprehensive Cancer Network recently released treatment guideline updates for esophageal and esophagogastric junction cancers, involving a systemic therapy in the second-line setting.
A recent comparative effectiveness study examined the effects of an insulin-sensitizing drug in patients who have suffered a stroke with a high risk for recurrent stroke or myocardial infarction vs those with a low risk.
Recent research has uncovered an association between tumor origin and mortality among patients receiving systemic chemotherapy plus biologic therapy for metastatic colorectal cancer.
The US Food and Drug Administration has indicated nivolumab for intravenous use in patients with previously treated liver cancer.
The US Food and Drug Administration expanded the approval of a targeted therapy to treat gastric or gastroesophageal junction cancer.
Results of eight recent clinical trials show that older patients treated for relapsed or refractory multiple myeloma with novel therapies had similar rates of progression-free survival as younger patients.
The National Comprehensive Cancer Network released updated guidelines for the treatment of basal cell skin cancer, squamous cell skin cancer, and merkel cell carcinoma.
A recent analysis examined the potential correlation between preexisting cardiovascular conditions and risk of heart failure in survivors of non-Hodgkin lymphoma.